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Mould invasive fungal infections (IFI) represent a major
complication in recipients of allogeneic haematopoietic cell
transplantation (allo-HCT). The most frequent and best-known
microorganism responsible for these IFI is Aspergillus spp. [1]
whereas infections from other pathogens, including Zygomy-
cetes and Hyalohyphomycetes, have been much less studied.
Data regarding non-Aspergillus IFI in the current era of allo-
HCT, with widespread use of antifungal prophylaxis and new
modalities of allo-HCT including reduced-intensity conditioning
and cord blood transplants, are scarce.
All consecutive allo-HCT patients prospectively reported to
the Infectious Disease Registry of the Spanish Haematopoietic
Transplant Group (GETH) between January 2009 andNovember
2011 were included. Patients were followed for at least 240 days
for death, relapse or IFI. Diagnosis of non-Aspergillusmould IFIwas
made according to the 2008 EORTC/MSG Consensus GroupClinical Microbiology and Infection © 2014 European Society of Ccriteria (European Organization for Research and Treatment of
Cancer/Invasive Fungal Infections Cooperative Group and the
National Institute of Allergy and Infectious Diseases Mycoses
StudyGroup) [2].Only provenor probable IFIwere included. The
study was approved by the GETH group board.
The primary endpoint of the study was the incidence of non-
Aspergillus mould IFI. Secondary objectives were description of
IFI characteristics and overall survival. Incidence of non-Asper-
gillus mold IFI was calculated using overall incidence estimates.
The probability of overall survival was estimated using
Kaplan–Meier curves.
Overall, 557 allo-HCT patients from 12 centres were
included. Most patients received reduced-intensity conditioning
allo-HCT (n = 308, 55%) while 249 (45%) received myeloablative
conditioning. Peripheral bloodwas used as the stem cell source in
412 patients (74%). Most transplants were performed from un-
related donors (n = 314, 56%), including 62 (11%) cord blood
transplants. Base-line diseases included acute leukaemia (n = 171,
31%), lymphoid malignancies (n = 145, 26%) and myelodysplastic
syndromes (n = 82, 16%). Most frequent graft-versus-host dis-
ease prophylaxis was based on a calcineurin inhibitor in combi-
nation with short-course methotrexate (n = 206, 37%). A total of
508 patients (91%) received antifungal prophylaxis in the neu-
tropenic phase of allo-HCT, mainly with ﬂuconazole
200–400 mg once a day (n = 226, 44%), posaconazole 200 mg
three times daily (n = 87, 17%) or a lipid formulation of
amphotericin B 1 mg/kg once a day (n = 75, 15%).
Seven (1.3%) patients developed a non-Aspergillus mould IFI
at a median of 137 days (range 64–236) post-transplant. All
these patients had received allo-HCT from unrelated donors
(ﬁve from volunteer unrelated donors, two from single cord
blood units). Only two patients were severely neutropenic
(<0.5 × 10E9/L) at the time of diagnosis. Six patients were being
treated with systemic corticosteroids for acute graft-versus-
host disease at diagnosis of the IFI and four of them were
receiving or had received >0.5 mg/kg for more than 10 days
during the 30 days before diagnosis of the IFI. Six of these pa-
tients had received antifungal prophylaxis during neutropenic
phase (voriconazole two patients, posaconazole two patients,
amphotericin one patient and ﬂuconazole one patient)
(Table 1).
The most commonly isolated fungi were Zygomycetes (n = 5),
followed by Pseudallescheria/Scedosporium complex and Micro-
ascus, one each. Four of these infections were proven and three
were probable according to the EORTC criteria [2]. Dissemi-
nated disease was observed in three patients (one patient with
sino-pulmonary infection, one case of rhino-cerebral infection
and one with cutaneous and pulmonary involvement). Two pa-
tients presentedwith isolated pulmonary infection, onewith sino-Clin Microbiol Infect 2015; 21: e1–e3
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TABLE 1. Demographic and clinical characteristics, diagnosis, treatments and evolution of patients with non-Aspergillus fungal
infections
UPN
Age (years)/
gender
Underlying
disease/HCT
Corticosteroids
at IFI diagnosis
ATF
prophylaxis IFI
Localization
IFI
Days after
HCT Treatment Evolution
131 16/female SAA/UCB Yes LFAB Rhizopus oryzae Pulmonary 188 LFAB,a caspofungin FRM
362 51/female AML/URD Yes Voriconazole Pseudallescheria /
Scedosporium
complex
Pulmonary 64 LFAB,a voriconazole,
surgery
Alive (+2 years)
759 60/male Myeloﬁbrosis/
URD
Yes No Rhizomucor spp. Bone 137 Amphotericin TRM
Resolved IFI
941 17/female ALL/URD No Voriconazole Cunninghamella
bertholletiae
Sinopulmonary 64 Posaconazole,a
terbinaﬁne, LFAB,
surgery
FRM
998 33/male AML/URD Yes Posaconazole Rhizomucor spp. Sino-orbital infection 68 LFAB,a caspofungin,
surgery
FRM
1085 24/male AML/URD Yes Fluconazole Microascus
trigonosporus
Pulmonary and cutaneous 219 Anidulafungin,a LFAB FRM
1095 59/female ALL/UCB Yes Posaconazole Rhizomucor spp. Rhino-cerebral 236 LFAB,a caspofungin,
surgery
FRM
Abbreviations: HCT, haematopoietic stem cell transplant; ALL, acute lymphoblastic leukaemia; SAA, severe aplastic anaemia; AML, acute myeloid leukaemia; UCB, umbilical cord
blood; URD, unrelated donor; LFAB, lipid formulation of amphotericin B; TRM, treatment-related mortality; IFI, invasive fungal infection; ATF, anti-fungal; FRM, fungal-related
mortality.
aAntifungal therapy was given simultaneously.
e2 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIorbital infection and one with isolated bone involvement. Six
patients were treated with antifungal combinations, given simul-
taneously, and one receivedmonotherapy (Table 1). Four patients
also underwent surgery: one with sino-orbital infection, one with
rhino-cerebral infection and the other twowith a large pulmonary
nodule. Six patients died at a median of 50 days (range 12–152
days) after diagnosis of IFI, ﬁve of them attributable to the fungal
infection. A single patient with pulmonary infection remains alive
after 2 years of follow up.
The present study conducted in a homogeneous population
of allo-HCT recipients, including current transplant modalities
and stem cell sources, reports a low incidence (1.3%) of non-
Aspergillus mould infections with very poor outcome.
Few studies have addressed the incidence of non-Aspergillus
mould IFI in allo-HCT patients. Reports from Italy and the USA
including heterogeneous populations of HCT recipients have
shown an overall incidence of these infections at 1 year of <1%.
The Seattle Group reported a slightly higher incidence although
this was an “earlier” cohort (1998–2002) not receiving anti-
mould prophylaxis [3–5]. In our study, we observed a slightly
higher incidence (1.3%) than most recent reports, probably
because only allo-HCT patients were considered, mostly from
unrelated donors. Unfortunately, data on the incidence of
Aspergillus and Candida infections were not available in our se-
ries. All infections were diagnosed >2 months after HCT, long
after the initial neutropenic phase. This delay in the occurrence
of ﬁlamentous IFI after HCT has been described for aspergillosis
[1] and might be related to the use of anti-mould prophylactic
agents during the neutropenic phase and the immunosuppres-
sive therapies used for treatment of graft-versus-host disease.
Also, the delayed immune reconstitution occurring in patients
receiving the aforementioned new modalities of HCT mightClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcontribute to the late development of these infections. The real
incidence of these infections is probably underestimated in all
studies, including ours, because deﬁnitive diagnosis usually re-
quires invasive diagnostic procedures, which are not always
feasible in allo-HCT patients. Regarding the outcome, the
overall mortality after non-Aspergillus ﬁlamentous IFI in our
patients was 85%, in line with other similar studies (65–80% at
12 weeks) [1].
Determination of possible risk factors for the development
of IFI was not possible in our study because of the low number
of cases. Risk factor studies on the development of non-Asper-
gillus ﬁlamentous IFI are lacking as they would require
extremely large populations of HCT recipients because of the
low incidence of these infections.
Predicting the relevance of non-Aspergillus mould IFI in the
allo-HCT population in the coming years is challenging. The
increased age of transplant recipients and the development of
new transplant modalities involving deeper and longer immu-
nosuppressive status might increase the incidence of these in-
fections. On the other hand, the use of mould antifungal
prophylaxis is increasing and might lower the risk of IFI in these
patients. Whether this widespread use of antifungal agents will
lead to an increase of resistant mould infections is still a matter
of debate. Finally, demographic characteristics should always be
considered because the incidence and most frequent isolates of
these IFI might vary among countries.
Our study of contemporary allo-HCT recipients shows a
low incidence of non-Aspergillus mould IFI in this setting. Careful
determination of risk factors for ﬁlamentous IFI and greater
efforts for prevention and early diagnosis seem necessary
because the outcome of the patients with established infection
is very poor.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, e1–e3
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